S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial (Q34588472)

3 August 2017

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial (English)

1 reference

3 August 2017

phase III clinical trial

0 references

1 reference

Wasaburo Koizumi

1

1 reference

3 August 2017

Hiroyuki Narahara

2

1 reference

3 August 2017

Takuo Hara

3

1 reference

3 August 2017

Akinori Takagane

4

1 reference

3 August 2017

Toshikazu Akiya

5

1 reference

3 August 2017

Masakazu Takagi

6

1 reference

3 August 2017

Kosei Miyashita

7

1 reference

3 August 2017

Takashi Nishizaki

8

1 reference

3 August 2017

Osamu Kobayashi

9

1 reference

3 August 2017

Wataru Takiyama

10

1 reference

3 August 2017

Yasushi Toh

11

1 reference

3 August 2017

Takashi Nagaie

12

1 reference

3 August 2017

Seiichi Takagi

13

1 reference

3 August 2017

Yoshitaka Yamamura

14

1 reference

3 August 2017

Kimihiko Yanaoka

15

1 reference

3 August 2017

Hiroyuki Orita

16

1 reference

3 August 2017

Masahiro Takeuchi

17

1 reference

3 August 2017

20 February 2008

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

9

1 reference

3 August 2017

215-221

1 reference

3 August 2017

3

1 reference

Epidemiology of gastric cancer and perspectives for prevention.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Epidemiology of gastric cancer in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Japanese Classification of Gastric Carcinoma - 2nd English Edition -

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970035-4

7 January 2021

10.1016/S1470-2045(08)70035-4

Identifiers

DOI

1 reference

release_mwjuvfrbqjcjbnvqqfqlvwuxpe

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mwjuvfrbqjcjbnvqqfqlvwuxpe

24 November 2022

mapped directly with Wikidata item

1 reference